Millipore and HyClone Align to Optimize Biopharmaceutical Drug Production.To download high-resolution, print-ready JPEG JPEG in full Joint Photographic Experts Group Standard computer file format for storing graphic images in a compressed form for general use. JPEG images are compressed using a mathematical algorithm. images, click on the thumbnail A miniature representation of a page or image that is used to identify a file by its contents. Clicking the thumbnail opens the file. Thumbnails are an option in file managers, such as Windows Explorer, and they are found in photo editing and graphics program to quickly browse multiple image above. WARNING: these images are very large (800K+) Click here for caption Business Editors/Health/Medical Writers MULTIMEDIA AVAILABLE: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=4558628 BIOWIRE2K BILLERICA, Mass., and LOGAN, Utah--(BUSINESS WIRE)--Jan. 27, 2004 Millipore Corporation For other uses, see Millipore. Millipore Corporation (NYSE: MIL) founded in 1954, listed among the S&P 500 since the early 1990s, is an international biosciences company, known widely for its micrometer pore-size filters and tests. (NYSE NYSE See: New York Stock Exchange : MIL), a multinational bioscience company, and HyClone Laboratories today announced the formation of a bioprocessing alliance. HyClone is a global leader in cell culture consumables and disposable bioprocess bi·o·proc·ess n. 1. A technique that produces a biological material, such as a genetically engineered microbial strain, for commercial use. 2. liquid containment containment Strategic U.S. foreign policy of the late 1940s and early 1950s intended to check the expansionist designs of the Soviet Union through economic, military, diplomatic, and political means. It was conceived by George Kennan soon after World War II. products and a subsidiary of Fisher Scientific Fisher Scientific, formally Fisher Scientific International, Inc. and colloquially Fisher was a biotechnology company that provided products and services to the global scientific research and United States clinical laboratory markets. International Inc. (NYSE: FSH FSH follicle-stimulating hormone. FSH abbr. follicle-stimulating hormone Facioscapulohumeral muscular dystrophy (FSH) ), a world leader in serving science. The alliance between Millipore and HyClone combines the critical elements required for value-added disposable manufacturing solutions. Biopharmaceutical manufacturers will have one supplier contact for the design, development, and validation See validate. validation - The stage in the software life-cycle at the end of the development process where software is evaluated to ensure that it complies with the requirements. support of disposable manufacturing systems combining HyClone bioprocess containers with various Millipore disposable separation products. Disposable processing systems received initial acceptance as cost-saving measures. Now, proven benefits include not only lower costs, but also less down-time, enhanced process security, greater process flexibility, and the capacity to facilitate greater speed-to-market. Disposable manufacturing also enables companies to run multiple products in a single plant without risking cross-contamination. "Both Millipore and HyClone have worked with pioneering biopharmaceutical companies to validate To prove something to be sound or logical. Also to certify conformance to a standard. Contrast with "verify," which means to prove something to be correct. For example, data entry validity checking determines whether the data make sense (numbers fall within a range, numeric data single-use disposable systems. Our collaborative efforts indicate that these companies are committing significant resources to the validation and implementation of disposable strategies," said Susan Vogt, President of Millipore's BioPharmaceutical division. Through this relationship, HyClone and Millipore will jointly address customers' needs for disposable combined products for pilot plant, process development and production applications. Future innovations required to meet evolving industry demands for combined products will come through the alliance partners' complementary R&D efforts in separation technology, connectology, and in validation, and applications engineering. "This alliance delivers the competencies and reliability required to support the continuing acceptance and growth of disposable biopharma manufacturing," said Leland Foster, President and Chief Executive Officer of Fisher Scientific's Biochemicals Group. "The expertise both companies bring to the effort can speed the drug development process and enhance customer process economics." As the industry advances in linking disposable technologies with existing stainless steel stainless steel: see steel. stainless steel Any of a family of alloy steels usually containing 10–30% chromium. The presence of chromium, together with low carbon content, gives remarkable resistance to corrosion and heat. and in replacing stainless steel, it is essential that Millipore and HyClone's single point resource for design, procurement The fancy word for "purchasing." The procurement department within an organization manages all the major purchases. , and support of combined products saves companies time, money, and effort. Offerings of combined products minimize peripheral components, reduce the incoming QC burden, and facilitate an integrated approach to the IQ/OQ/PQ IQ/OQ/PQ Installation Qualification, Operational Qualification, Performance Qualification (validation of equipment) validation process. Combining Millipore's global sales and support functions with HyClone's film and container expertise ensures an unparalleled approach to providing fully integrated disposable solutions. This is a step toward the future "Plastic Factory" vision, which describes a complete manufacturing process constructed entirely of disposable, single-use flow paths. About Millipore Millipore is a multinational bioscience company that provides technologies, tools and services for the discovery, development, and production of new therapeutic drugs. It serves the life science research, biotechnology, and pharmaceutical industries. For more information about Millipore visit www.millipore.com. About HyClone HyClone is a global manufacturer of sera, liquid and powdered media, sterile sterile /ster·ile/ (ster´il) 1. unable to produce offspring. 2. aseptic. ster·ile adj. 1. Not producing or incapable of producing offspring. 2. liquids, and sterile liquid handling systems to support research and production of biopharmaceuticals. HyClone is owned by Fisher Scientific International. For more information about HyClone visit the web site at www.hyclone.com or phone 435-792-8000 or toll-free 1-800-492-5663. About Fisher Scientific International Inc. As a world leader in serving science, Fisher Scientific International Inc. (NYSE: FSH) offers more than 600,000 products and services to more than 350,000 customers located in approximately 145 countries. As a result of its broad product offering, electronic-commerce capabilities and integrated global logistics network, Fisher serves as a one-stop source of products, services and global solutions for its customers. The company's primary target markets are life science, clinical laboratory and industrial-safety supply. Additional information about Fisher is available on the company's Web site at www.fisherscientific.com. Millipore Forward Looking Statement Disclaimer The matters discussed herein, as well as in future oral and written statements by management of Millipore Corporation that are forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. , are based on current management expectations that involve substantial risks and uncertainties which could cause actual results to differ materially from the results expressed in, or implied by, these forward-looking statements. Potential risks and uncertainties that could affect Millipore's future operating results include, without limitation, foreign exchange rates; regulatory delay in the approval of new therapeutics therapeutics Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry. and their ultimate commercial success; further consolidation of drug manufacturers; competitive factors such as new membrane technology; lack of availability of raw materials or component products on a timely basis; inventory risks due to shifts in market demand; change in product mix; conditions in the economy in general and in the bioscience markets in particular; potential environmental liabilities; the inability to utilize technology in current or planned products due to overriding (programming) overriding - Redefining in a child class a method or function member defined in a parent class. Not to be confused with "overloading". rights by third parties; difficulties inherent in research and development activities; and the risk factors listed from time to time in Millipore's filings with the SEC. Fisher Forward Looking Statement This announcement includes forward-looking statements. Fisher Scientific has based these forward-looking statements on its current expectations and projections about future events. Although Fisher Scientific believes that its assumptions made in connection with the forward-looking statements are reasonable, no assurances can be given that its assumptions and expectations will prove to have been correct. These forward-looking statements are subject to various risks, uncertainties and assumptions. Fisher Scientific undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. In light of these risks, uncertainties and assumptions, the forward-looking events discussed in this announcement might not occur. Millipore is a registered trademark of Millipore Corporation and HyClone is a registered trademark of HyClone Laboratories Inc. MULTIMEDIA AVAILABLE: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=4558628 |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion